4D Molecular Therapeutics, Inc. Increase (Decrease) in Contract with Customer, Liability
4D Molecular Therapeutics, Inc. (FDMT) reported Increase (Decrease) in Contract with Customer, Liability of $2.21 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was $830.00K.
- 4D Molecular Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was $1.38M.
- 4D Molecular Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$90.00K.
- 4D Molecular Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$90.00K.
- 4D Molecular Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2025 was -$209.00K, a 402.90% decline from fiscal 2024.
- 4D Molecular Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was $69.00K.
- 4D Molecular Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was -$715.00K.
- 4D Molecular Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was -$3.13M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $830.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.21M 10-Q · filed 2026-08-13 | $2.12M derived: sum of 3 quarters · filed 2026-08-13 | $2.03M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.38M 10-Q · filed 2026-05-07 | $1.29M derived: sum of 2 quarters · filed 2026-05-07 | $1.20M derived: sum of 3 quarters · filed 2026-05-07 | $1.19M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$90.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$180.00K derived: sum of 2 quarters · filed 2026-03-18 | -$195.00K derived: sum of 3 quarters · filed 2026-08-13 | -$209.00K 10-K · filed 2026-03-18 |
| 2025-09-30 | -$90.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$105.00K derived: sum of 2 quarters · filed 2026-08-13 | -$119.00K 10-Q · filed 2025-11-10 | -$119.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$15.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$29.00K 10-Q · filed 2026-08-13 | -$29.00K derived: sum of 3 quarters · filed 2026-08-13 | -$32.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$14.00K 10-Q · filed 2026-05-07 | -$14.00K derived: sum of 2 quarters · filed 2026-05-07 | -$17.00K derived: sum of 3 quarters · filed 2026-05-07 | -$22.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$3.00K derived: sum of 2 quarters · filed 2026-03-18 | -$8.00K derived: sum of 3 quarters · filed 2026-03-18 | $69.00K 10-K · filed 2026-03-18 |
| 2024-09-30 | -$3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$8.00K derived: sum of 2 quarters · filed 2025-11-10 | $69.00K 10-Q · filed 2025-11-10 | $88.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $72.00K 10-Q · filed 2025-08-11 | $91.00K derived: sum of 3 quarters · filed 2025-08-11 | -$105.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $77.00K 10-Q · filed 2025-05-08 | $96.00K derived: sum of 2 quarters · filed 2025-05-08 | -$100.00K derived: sum of 3 quarters · filed 2025-05-08 | -$340.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$177.00K derived: sum of 2 quarters · filed 2025-02-28 | -$417.00K derived: sum of 3 quarters · filed 2025-02-28 | -$715.00K 10-K · filed 2025-02-28 |
| 2023-09-30 | -$196.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$436.00K derived: sum of 2 quarters · filed 2024-11-13 | -$734.00K 10-Q · filed 2024-11-13 | -$1.98M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$240.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$538.00K 10-Q · filed 2024-08-08 | -$1.79M derived: sum of 3 quarters · filed 2024-08-08 | -$2.29M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$298.00K 10-Q · filed 2024-05-09 | -$1.55M derived: sum of 2 quarters · filed 2024-05-09 | -$2.05M derived: sum of 3 quarters · filed 2024-05-09 | -$2.21M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$1.75M derived: sum of 2 quarters · filed 2024-02-29 | -$1.91M derived: sum of 3 quarters · filed 2024-02-29 | -$3.13M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$663.00K derived: sum of 2 quarters · filed 2023-11-09 | -$1.88M 10-Q · filed 2023-11-09 | -$1.53M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$163.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$1.38M 10-Q · filed 2023-08-09 | -$1.03M derived: sum of 3 quarters · filed 2023-08-09 | -$1.65M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$1.22M 10-Q · filed 2023-05-11 | -$867.00K derived: sum of 2 quarters · filed 2023-05-11 | -$1.49M derived: sum of 3 quarters · filed 2023-05-11 | -$14.91M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $352.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$268.00K derived: sum of 2 quarters · filed 2023-03-15 | -$13.69M derived: sum of 3 quarters · filed 2023-03-15 | -$14.72M 10-K · filed 2023-03-15 |
| 2021-09-30 | -$620.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$14.04M derived: sum of 2 quarters · filed 2022-11-08 | -$15.07M 10-Q · filed 2022-11-08 | -$12.61M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$13.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$14.45M 10-Q · filed 2022-08-11 | -$11.99M derived: sum of 3 quarters · filed 2022-08-11 | -$13.52M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$1.03M 10-Q · filed 2022-05-12 | $1.43M derived: sum of 2 quarters · filed 2022-05-12 | -$98.00K derived: sum of 3 quarters · filed 2022-05-12 | $2.00M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $2.46M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $937.00K derived: sum of 2 quarters · filed 2022-03-28 | $3.03M derived: sum of 3 quarters · filed 2022-03-28 | $345.00K 10-K · filed 2022-03-28 |
| 2020-09-30 | -$1.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $569.00K derived: sum of 2 quarters · filed 2021-11-10 | -$2.12M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $2.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$592.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$2.69M 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | -$3.35M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |